News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Valerie L. Staradub, MD

Advertisement

Articles by Valerie L. Staradub, MD

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

ByNatalie Garver,Valerie L. Staradub, MD,Christopher Verdone,Kelly Mackessy,Alexandra Haraczy,Lianteng Zhi
May 20th 2025

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

ByKelly Mackessy,Christopher Verdone,Karisa Beebe,Valerie L. Staradub, MD,Candice Ford,Kristen Skonieczny,Alexandra Haraczy,Alexandra Ford,Hyeon Jeong,Esha Parikh,Dawn Johnson Leonard
May 24th 2024

10 Wire Localization vs Radar Reflector Localization: A Comparison

ByKarisa Beebe,Elissa Dalton,Candice Ford,Lianteng Zhi,Karen Louie,Dawn J. Leonard,Dennis Witmer,Christopher Verdone,Jennifer Sims Mourtada,Valerie L. Staradub, MD
April 26th 2023

Management of Patients at High Risk for Breast Cancer

ByVictor G. Vogel, MD, MHS, FACP,Valerie L. Staradub, MD
January 1st 2002

Management of Patients at High Risk for Breast Cancer, edited by Victor G. Vogel, MD, is designed for all physicians involved in breast cancer risk assessment and prevention. It does not assume a baseline familiarity with cancer risk

Advertisement

Latest Updated Articles

  • Management of Patients at High Risk for Breast Cancer
    Management of Patients at High Risk for Breast Cancer

    January 1st 2002



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

2

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

3

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

4

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

5

Achieving a “Functional Cure” With Multiple Myeloma Therapy

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us